Havn Life Sciences

Press

HAVN Life Provides Corporate Update

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP) announces that the board of directors of the Company, on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due. A restructuring plan…

Havn Life Sciences

Press

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments‎ and the Issuance of Shares for Debt

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche of its financing commitment by Alpha Blue Ocean that was previously announced on July 21, 2022. The Company intends…

Havn Life Sciences

Press

HAVN Life Announces Financing Commitment of C$9,000,000 through the issuance of Convertible Debentures and Warrants

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that Alpha Blue Ocean is supporting the Company’s growth with a CAD$‎‎9,000,000 ‎‎financing arrangement whereby the Company will issue up to $10.6 million principal amount of Convertible Debentures…

Havn Life Sciences

Press

HAVN Life Expands Supply Agreement with Mycotopia Therapies Inc.

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has expanded its supply partnership with Mycotopia Therapies Inc., adding a second supply agreement that covers functional mushrooms, HAVN Life’s recently launched natural health products, as well as white label…